The Valley Desk

NCT01064401 · Interventional trial

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

Overall registry status Completed

Phase 3

Conditions Relapsing-Remitting Multiple Sclerosis

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov